Abstract
Introduction
The immunotherapy field in cancer has never been more potent than it is right
now, including block buster drugs like Avastin, Erbitux, and Rituxan.
Antibodies are making the headlines but cancer vaccines are not far away. The
recent approval of Gardasil, a cervical cancer vaccine, will certainly become
a strong representative of its kind. Future challenges for the industry lie in
discovering strong antigens, effective immunomodulators and developing
suitable delivery technologies.
Scope of this report
- In-depth competitive landscape assessment of the cancer immunotherapy
market place; Including more than 200 immunotherapy drugs and pharmaceutical
companies
- Thorough review of tumor antigen discovery, immunomodulating strategies
and adjuvants
- Thorough review of antibody and vaccine delivery and technologies
surrounding it - The next generation
- Progress analysis of six major cancer vaccine indications and late stage
antibody development projects, including players, drugs, clinical progress and
pitfalls
Research and analysis highlights
Among the targeted therapies for cancer, immunotherapy is probably the most
versatile treatment strategy for the eradication of tumors, metastatic spread
or not. Main strategies of cancer immunotherapy aim at exploiting the
therapeutic potential of tumor-specific antibodies and cellular immune
effector mechanisms (vaccines). Active immunotherapy, aiming at the generation
of a tumor-specific immune response combining both humoral and cytotoxic T
cell effector mechanisms by the host's immune system, is advancing over
passive antibody therapy, which relies on the repeated application of large
quantities of tumor antigen-specific antibodies.
View Cart
